Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).

Trial Details

NCT ID
NCT07032714
Phase
PHASE1
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Talquetamab
  • Mezigdomide
  • Dexamethasone
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medica…
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix).
  • Age ≥ 18 years
  • Measurable disease of multiple myeloma as defined by at least one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →